I am unashamedly passionate about lupus. Since a serendipitous meeting with Edmund Dubois in August, 1977, my life has not been the same. Having seen three thousand patients with lupus and after attending all too many funerals over 30 years, I find it outrageous that no new agents have been approved for the disease in the United States. I am still using ibuprofen, naproxen, antimalarials, corticosteroids, methotrexate, azathioprine, cyclophosphamide and apheresis, all of which were in my 30-year-old armamentarium. With the exception of mycophenolate mofetil, I am operating in a time warp. Even though my patients are living longer with better antihypertensives, anti-transplant rejection regimens, antibiotics, smoking cessation, osteoporosis management strategies, improved diagnostic imaging and antiatherogenesis vigilance, their quality of life has only marginally improved. Half of my newly diagnosed married female patients divorce within 5 years, most are disabled within 10 years, many have poor coping mechanisms, and there is still precious little coordination between the primary care physician and lupus specialist.
In 2005, the greatly appreciated efforts of Peter Lipsky, Lee Simon, the Lupus Foundation of America, SLE Foundation and other lupus support organizations led to the formulation and ultimate publication of guidelines to industry on how to shepherd a drug to market in the Federal Register. 1 This ended the pathetic roller coaster where well-meaning efforts by a company such as Genelabs to study Prasterone were given several different and conflicting sets of instructions on how to undertake a lupus clinical trial by bureaucrats du jour. The unfortunate series of events over the last 4 years is well documented by my esteemed friends and colleagues-Drs Isenberg, Gordon, Urowitz and Merrill-in their editorial under the same title in this journal. 2 To summarise their wellarticulated eight points, patients in clinical trials should have lupus, the study must be conducted by practitioners familiar with the disease, familiar with the british isles lupus assessment group (BILAG) and Systemic lupus erythematosus disease activity index (SLEDAI) as well as having the ability to attribute clinical findings to the disease as opposed to medication, infection or a coexisting condition. Also, since high-dose oral corticosteroids are highly effective, they blur trial distinctions and confound trial design. Finally, haematuria may be acceptable as an inclusion criteria but it is impossible to follow in menstruating women and opens up a can of worms.
The last 10 years have seen lupus trials studying useful agents fail for a variety of reasons. In my opinion, based on analysis of published data, they include 1) Assuming patients receiving corticosteroids really needed the dose they were prescribed, which turned out not to be the case (Prasteronedehydroepiandrosterone (DHEA)) 2) Using published data from centres treating seriously ill patients to estimate nephritis flare rates for centres treating less seriously ill patients resulting in an underpowered study (LJP 394) 3) Enrolling patients who purportedly met American College of Rheumatology (ACR) criteria for SLE but had a negative ANA (belimumab) 4) Giving both arms of a study highly effective treatments, ignoring the lessons of the early 1980s apheresis/cyclophosphamide/prednisone national institutes of health (NIH) sponsored protocol (rituximab) 5) Inability to maintain a supply of the study drug (epratuzumab) 6) Failure to study a higher dose of an agent for financial reasons, which turned out to be more effective (LJP 394) 7) Recruitment of specific sites with unusually high mortality rates or unusually high response rates (Aspreva lupus maintenance study (ALMS) mycophenolate trial, cannot release drug name due to confidentiality agreement) 8) Pressure by a federal agency to conduct a superiority trial (as opposed to an equivalence one) with a non-approved comparator drug for lupus which is more toxic than the study drug (ALMS mycophenolate trial) 9) Mandating moderately high steroid dosing in both study arms with tapering before the study drug became effective resulting in both arms having equivalent BILAG flare rates (abatacept) 10) Drug toxicity or underpowering of a study with too short a duration (anti CD40L from Biogen and Idec, respectively) 11) Inadequate guidance from regulatory agencies for studies completed before 2006 (Prasterone, LJP 394, anti CD40L)
In 2008, lupus trials proposed or in progress from Wyeth, Merck/Serono, Genentech and Rigel were put on hold or discontinued. Hopefully, we have learned from the lessons enumerated by my colleagues in the previous editorial and the points listed above. The purpose of this commentary is to add several additional suggestions based on my experience which are discussed below (and may well be politically incorrect) to ensure the success of a putative successful agent:
1) Use the wisdom and experience of practitioners who treat large numbers of patients with lupus in designing a clinical trial: Some of the best and most brilliant lupus basic science physicians see very few, if any, patients with lupus. Their input is important at advisory boards, but all too few of these convocations include clinicians (especially private practitioners) who treat patients with lupus. Interestingly, the majority of lead authors in the successful rheumatoid arthritis trials published in the last 10 years are in private practice (e.g., Weaver, Schiff, Fleischmann, Cohen, Kremer). Two biologic studies had no practicing rheumatologist input on their (ultimately negative) trial design. 2) Make use of a quality rheumatology laboratory and address chronic laboratory issues: Why does nearly every trial studying moderate to seriously active lupus contract with a clinical laboratory which uses anti-dsDNA by enzyme immunoassay (EIA) obtain 'greater than 200' each time the test is run so that following anti-dsDNA is worthless? Either use the Farr assay or quantitate anti-dsDNA to its actual value. Why do so many studies obtain anti-Sm, RNP, SSA and SSB at each visit when these serologies rarely, if ever change, and their quantitation is of no use? Also, on site complete blood counts (CBCs) should be allowed because platelets in patients with lupus tend to clump, especially when travelling thousands of miles to reference laboratories and 10-20% of the time the patient is called back to repeat the test. Some studies are looking at interferon signature as a candidate biomarker as well. 10) The perfect study will never meet enrolment goals: Studies that do not mandate corticosteroids and those that allow community standard background therapy enrol quickly (e.g., the Phase III belimumab clinical trials enrolled 1500 patients in less than a year). Nephritis studies enrol slowly, especially if they mandate red cell casts and a recent biopsy. Improvements in lupus trial design invariably make it more difficult to attract patients. The 'perfect study' can take up to 5 years to complete enrolment. Flexibility and practicality are important.
3) A central SLEDAI and BILAG validation mech
Lupologists are greyer and wiser. A successful clinical trial is now within our grasp. Termed the paradigm of autoimmunity, advances in the treatment of the disease will have translational effects to other immune disorders and increase the understanding of its pathophysiology. We have learned our lessons, let us now proceed with deliberate speed.
